Yahoo Finance Plus 
The pandemic caused supply chains to slow to a crawl, making it challenging for retailers to secure inventory. Tilly's (NYSE: TLYS) was fortunate, earning record profits in the quarters following its reopening. In its first quarter of 2022, which ended on April 1, Tilly's net sales decreased by 10.7%.
Harriet Hageman says the Wyoming representative didn't actually concede after losing on Election Night, but Cheney has the receipts
In this article, we discuss the 5 stocks that Warren Buffett is buying on the dip. If you want to see more stocks in this selection, click Warren Buffett is Buying the Dip on These 3 Stocks. Berkshire Hathaway’s Warren Buffett went on a buying spree despite the turmoil in the global equity markets. In […]
Shares of StoneCo (NASDAQ: STNE), a cloud-based technology platform, plummeted Friday morning after the company reported its second-quarter results, which disappointed investors, and announced yet another shift to its management team. The company reported non-GAAP (adjusted) earnings of 0.25 Brazilian reals (equivalent to $0.05), which was an increase from a loss of 0.48 reals in the year-ago quarter, but was below Wall Street's consensus estimate of about 0.57 reals, or $0.11 per share. StoneCo's revenue in the quarter was 2.3 billion reals (about $442 million), 5% higher than the company's guidance, and up 275% from the year-ago quarter.
Yahoo Finance Live’s Brian Cheung and Brian Sozzi discuss why retail traders are angry at activist investor Ryan Cohen for selling his remaining stake in BBBY stock.
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D). Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood. Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high. Related: Aeglea BioTherapeutics Shares
A lot of surprising companies are paring back their payrolls lately. Some of them should bounce back soon.
Yahoo Finance's Brian Cheung discusses reports that a depression drug from Axsome Therapeutics has gotten FDA clearance.
(Bloomberg) -- The US mortgage industry is seeing its first lenders go out of business after a sudden spike in lending rates, and the wave of failures that’s coming could be the worst since the housing bubble burst about 15 years ago. Most Read from BloombergXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesUS Mortgage Lenders Are Starting to Go BrokeCovid’s Harmful Effects on the Brain Reverberate Years LaterBiden's Ne
The past few weeks have been refreshing for Cathie Wood and fans of her style of growth stock investing. The CEO and co-founder of Ark Invest publishes the buys and sells of her firm's exchange-traded funds (ETFs) every market day, giving the public insight into her latest allocation strategies.
How much money people have put away for retirement naturally varies by age. See how your savings stack up.
Verizon (VZ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NIO Inc. (NIO) closed at $19.91 in the latest trading session, marking a -0.85% move from the prior day.
StoneCo Ltd. (STNE) delivered earnings and revenue surprises of -54.55% and 10.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance anchors report that Bed Bath & Beyond stock tanked on Friday morning, falling by the most since January 2021.
Yahoo Finance Live anchors discuss Bed Bath & Beyond stock performance after activist investor Ryan Cohen completes his sale of shares.
JPMorgan Chase & Co. (JPM) closed at $121.64 in the latest trading session, marking a -0.77% move from the prior day.
(Bloomberg) -- One big force at the center of the two-month equity rally is showing signs of fatigue. Most Read from BloombergXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesUS Mortgage Lenders Are Starting to Go BrokeCovid’s Harmful Effects on the Brain Reverberate Years LaterBiden's Next Grand Bargain Could Retire TrumpIt’s the behavior of short sellers, whose frantic efforts to unwind bearish wagers created buying
BlackCloak CEO Chris Pierson joins Yahoo Finance Live to discuss Apple’s security vulnerabilities, why Apple users should update their devices, and the outlook for cyberattacks.
It is well-known that the cost of college has been increasing in the U.S., typically much faster than inflation. Although the rate of inflation has been higher recently, it tends to be around 2%....
On Friday, Rocky Fishman, the head of index volatility research at Goldman, sent a chart to MarketWatch illustrating the different types of stock-linked options that are set to expire, as well as whether they’re set to expire in the morning, or in the afternoon in New York. As Fishman explained in a note in June, options expiration adds a layer of “positioning complexity” to the market. Since the Federal Reserve announced its second 75 basis points interest-rate hike in July, market strategists including JPMorgan Chase & Co.’s Marko Kolanovic have cited positioning as the critical factor driving markets higher, as investors chased the rally by putting money back to work in the market.
Yahoo Finance